Clinical Trials Logo

Diabetic Cardiomyopathy clinical trials

View clinical trials related to Diabetic Cardiomyopathy.

Filter by:
  • None
  • Page 1

NCT ID: NCT05102851 Completed - Clinical trials for Diabetic Cardiomyopathy

Impact of Prediabetes on Acute Coronary Syndrome

Start date: August 1, 2021
Phase:
Study type: Observational [Patient Registry]

Diabetes mellitus is one of the chronic non-communicable diseases which have emerged as a leading global health problem. According to the International Diabetes Federation Atlas guideline report, currently, there are 352 million adults with impaired glucose tolerance who are at high risk of developing diabetes in the future. In 2017, it was estimated that 425 million people (20-79 years of age) suffered from Diabetes mellitus, and the number is expected to rise to 629 million by 2045. Moreover, Egypt is considered one of the top 10 countries in the world

NCT ID: NCT03904485 Active, not recruiting - Clinical trials for Diabetic Cardiomyopathy

Assessment of Myocardial Injury in Simultaneous Pancreas and Kidney Transplantation

AMI-SPK
Start date: April 1, 2019
Phase:
Study type: Observational

Diabetic cardiomyopathy( DCM) is a major complication of diabetes and is a common cardiovascular complication independent of coronary artery disease and hypertension.Trial to assess of myocardial injury in recipients of simultaneous pancreas and kidney transplantation by nuclear magnetic T2 mapping technology.

NCT ID: NCT01803828 Completed - Clinical trials for Diabetes Mellitus Type 2

REmodelling in Diabetic CardiOmapathy: Gender Response to PDE5i InhibiTOrs

RECOGITO
Start date: May 2014
Phase: Phase 4
Study type: Interventional

Pathophysiology of diabetic cardiomyopathy (DCM) is yet unclear and gender differences at baseline and a specific treatment have not been indicated. The investigators already demonstrated the positive impact of phosphodiesterase type 5A (PDE5A) inhibition in men. The investigators' study aims to characterize DCM, measuring molecular and neuroendocrine assessment to relate to intramyocardial metabolism and cardiac kinetic. The investigators will perform a randomized, placebo-controlled, double-blind study enrolling 164 diabetic patients (females and males) with DCM, to evaluate gender responses to 6 months of PDE5A inhibitors (PDE5Ai). The investigators' study will describe gender differences in DCM features. The proposed research will test whether PDE5Ai could become a new target for antiremodeling drugs and to discover a molecular pathways affected by this class of drugs and a network of circulating markers for the early diagnosis, monitoring and prediction of response to treatment of DCM.

NCT ID: NCT00628056 Recruiting - Clinical trials for Diabetic Cardiomyopathy

Mechanisms Responsible for Cardiac and Skeletal Muscle Energetic Impairment in Diabetes

DDCM
Start date: October 2006
Phase: Phase 1/Phase 2
Study type: Interventional

Diabetes increases the risk of heart failure. This is mainly due to a disease of the blood vessels supplying the heart muscle and/or high blood pressure, but abnormal metabolism may also contribute. We plan to study the mechanisms involved in this abnormal metabolism, whilst also assessing the effects of a drug called Perhexiline which improves the abnormal metabolism that is present in diabetic patients before the development of heart failure.